Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Techno Drugs's Enterprise Value is BDT9,023 Mil.
Techno Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was BDT691 Mil. Therefore, Techno Drugs's EV-to-EBIT ratio for today is 13.06.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Techno Drugs's Enterprise Value is BDT9,023 Mil.
Techno Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT691 Mil. Therefore, Techno Drugs's EV-to-EBITDA ratio for today is 13.06.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Techno Drugs's Enterprise Value is BDT9,023 Mil.
Techno Drugs's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was BDT3,102 Mil. Therefore, Techno Drugs's EV-to-Revenue ratio for today is 2.91.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Techno Drugs's Enterprise Value is BDT9,023 Mil.
Techno Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-602 Mil. Therefore, Techno Drugs's EV-to-FCF ratio for today is -15.00.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Techno Drugs (DHA:TECHNODRUG) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Techno Drugs's current Enterprise Value is BDT9,023 Mil.
Techno Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT691 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Techno Drugs's current Enterprise Value is BDT9,023 Mil.
Techno Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT691 Mil.
Techno Drugs's current Enterprise Value is BDT9,023 Mil.
Techno Drugs's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT3,102 Mil.
Techno Drugs's current Enterprise Value is BDT9,023 Mil.
Techno Drugs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT214 Mil.
Techno Drugs's current Enterprise Value is BDT9,023 Mil.
Techno Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-602 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs Enterprise Value Related Terms
Techno Drugs Enterprise Value Historical Data
* Premium members only.
The historical data trend for Techno Drugs's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Techno Drugs's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Techno Drugs's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of BDT9,023 Mil mean?
Techno Drugs (DHA:TECHNODRUG) has a Enterprise Value of BDT9,023 Mil as of Jul. 24, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Techno Drugs and its competitors.
Is Techno Drugs' Enterprise Value too high?
Techno Drugs' current Enterprise Value is BDT9,023 Mil. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Enterprise Value compare to ZTS and UTHR?
Techno Drugs' Enterprise Value of BDT9,023 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Techno Drugs and its competitors. Techno Drugs's current Enterprise Value is BDT9,023 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Enterprise Value of BDT9,023 Mil. The current Enterprise Value is BDT9,023 Mil. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Enterprise Value is BDT9,023 Mil as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
